Tamoxifen improves survival in male breast cancer patients, finds study

Medically Reviewed By : Dr. Kamal Kant Kohli

Published On 2020-07-28 15:15 GMT | Update On 2020-07-29 11:35 GMT

Germany: Tamoxifen treatment improves disease-free survival (DFS) in male breast cancer (MBC) patients, suggests a recent study in the British Journal of Cancer.

About 1% of all breast cancer occurs in males. The current treatment of male breast cancer (MBC) is based on information obtained by extrapolation from studies on female patients due to the lack of prospective data.

Tamoxifen is known to reduce breast cancer mortality and recurrence risk in early-stage hormone receptor (HR)-positive breast cancer. Holm Eggemann, Otto-von-Guericke University, Magdeburg, Germany, and colleagues retrospectively examined the survival effect of tamoxifen in MBC patients.

This prospectively enrolled cohort study involved 448 patients (with a median age at diagnosis of 69 years) with MBC. They were treated between May 2009 and June 2018. The primary endpoint was disease-free survival.

Key findings of the study include:

Most tumours were larger than 20 mm; invasive ductal carcinoma was of no special histological type and with an intermediate grade of differentiation.
Almost half of the men were diagnosed with positive axillary lymph nodes (43.5%).
Hormone receptor (HR) positivity was observed in 98.4% of the patients.
DFS among men who did not receive tamoxifen was significantly reduced as compared with those who underwent tamoxifen therapy.
The recurrence rate and mortality in the group of patients without and with tamoxifen treatment were 18.2% and 11.2%, respectively.
The most common localisation of metastases was the bone.
After adjustment for prognostic factors, we found that tamoxifen was found to reduce the recurrence rate by 68% (hazard ratio HR = 0.32).

"Tamoxifen treatment was associated with improved DFS for MBC patients," concluded the authors.

The study, "Survival benefit of tamoxifen in male breast cancer: prospective cohort analysis," is published in the British Journal of Cancer.

DOI: https://doi.org/10.1038/s41416-020-0857-z

Article Source : British Journal of Cancer

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Medha Baranwal

Comments Policy

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Tamoxifen improves survival in male breast cancer patients, finds study

Similar News

High Sucralose Intake May Lower Effectiveness of Immune Checkpoint Inhibitors in Cancer Patients: Study

FDA Authorizes ProSense Cryoablation System for Early-Stage Breast Cancer in Older Women

9/11 study shows how toxic exposures may lead to blood cancers

Inflammation Markers Help Predict AKI After Bladder Cancer Surgery, reports study

Radiation exposure from imaging in children increased risk of hematologic cancer: NEJM

Adjuvant Radiotherapy or ET Lowers Locoregional Recurrence Rates Risk in Early-Stage Breast Cancer: JAMA

Roche bags USFDA nod for Tecentriq plus lurbinectedin for extensive-stage small cell lung cancer

Pneumococcal Vaccination in Hematological Malignancies (HM)-Indian Hematology Expert Consensus 2025